PharmAust and LUMC will now progress the antiviral development program to testing in human cells.
MPLS shows antiviral activity reaching 95%.
GMP-quality MPL production for human clinical trials has commenced at Syngene International Ltd (India).
PAA clinical development plans remains unchanged.
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-11
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.5¢ | 19.5¢ | $459.0K | 2.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 103700 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 127225 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |